Taiwan vaccine company presents Phase II trial data

Photo for illustrative purposes only. (Photo courtesy of NOWnews)

TAIPEI (The China Post) — Taiwan-based pharmaceutical company Medigen Vaccine Biologics Corporation (高端疫苗生物製劑股份有限公司) on Thursday presented the data recorded from their Phase II trial, reporting no significant adverse side effects among participants.

Medigen Spokesperson Leo Lee (李思賢) reported that the 4,000 plus participants received their second dose of the vaccine on April 28 and had a follow-up examination one month later.

The Phase III trial will soon be underway, the spokesperson said, before adding that the data compiled today by the third-party contracted vaccine research organization will be sent to Taiwan’s Food and Drug Administration (FDA, 食藥署).

The application for Emergency Use Authorization (EUA) will also be sent, and the company hopes that the vaccines can be distributed soon.